Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 03/29 05:35:17 pm
1678.5 GBp   +0.09%
02:38p FDA, Mylan silence on generic Advair may be good news for GSK
01:43p British business navigates rocky path to Brexit
09:53a GLAXOSMITHKLINE : Selling GSK would be a mistake
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
02:38p FDA, Mylan silence on generic Advair may be good news for GSK
01:43p British business navigates rocky path to Brexit
09:53a GLAXOSMITHKLINE : Selling GSK would be a mistake
03/28 GLAXOSMITHKLINE : What to do with GSK
03/28 PFIZER : MSF launches new strategies to help gov'ts buy 'expensive' pneumonia va..
03/23 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Detail Findings in Glutam..
03/23 GLAXOSMITHKLINE : Reports Findings in Relapsing-Remitting Multiple Sclerosis (Le..
03/23 GLOBAL NICOTINE GUM CONSUMPTION MARK : Reynolds American, Cambrex Corporation, F..
03/23 GLAXOSMITHKLINE : *socgen cuts glaxosmithkline price target to 1300 pence - 'sel..
03/17 GLAXOSMITHKLINE : *berenberg raises glaxosmithkline price target to 1890 pence -..
More news
Sector news : Pharmaceuticals - NEC
02:38p FDA, Mylan silence on generic Advair may be good news for GSK
01:43p British business navigates rocky path to Brexit
09:52a ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:23a FDA nominee Gottlieb had financial relationships with range of healthcare com..
03/27 My Favorite Biotech Takeover Play
03/24 WORD ON WALL STREET : Investors Focused On Mylan's Advair Generic, Not EpiPens
03/24 Is Now Too Soon To Buy Adaptimmune?
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
Advertisement
Financials ( GBP)
Sales 2017 30 019 M
EBIT 2017 8 460 M
Net income 2017 4 189 M
Debt 2017 14 129 M
Yield 2017 4,77%
P/E ratio 2017 20,27
P/E ratio 2018 17,39
EV / Sales 2017 3,22x
EV / Sales 2018 3,09x
Capitalization 82 457 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,6  GBP
Spread / Average Target 4,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC7.36%102 251
JOHNSON & JOHNSON9.19%340 651
ROCHE HOLDING LTD.8.73%221 256
PFIZER INC.5.17%203 427
NOVARTIS AG-0.34%196 620
MERCK & CO., INC.7.59%173 904
More Results